Follow
Alberto Gil Jimenez
Title
Cited by
Cited by
Year
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
N van Dijk, A Gil-Jimenez, K Silina, K Hendricksen, LA Smit, JM de Feijter, ...
Nature medicine 26 (12), 1839-1844, 2020
2832020
Assessment of predictive genomic biomarkers for response to cisplatin-based neoadjuvant chemotherapy in bladder cancer
A Gil-Jimenez, J van Dorp, A Contreras-Sanz, K van der Vos, DJ Vis, ...
European urology 83 (4), 313-317, 2023
182023
The tumor immune landscape and architecture of tertiary lymphoid structures in urothelial cancer
N Dijk, A Gil-Jimenez, K Silina, ML Montfoort, D Peters, J Sanders, ...
Frontiers in Immunology 12, 793964, 2021
112021
Atezolizumab with or without radiotherapy for advanced squamous cell carcinoma of the penis (the PERICLES study): a phase II trial
HM de Vries, TS Rafael, A Gil-Jimenez, JM de Feijter, E Bekers, ...
Journal of Clinical Oncology 41 (31), 4872-4880, 2023
102023
Biomarker analysis and updated clinical follow-up of preoperative ipilimumab (ipi) plus nivolumab (nivo) in stage III urothelial cancer (NABUCCO).
N Van Dijk, A Gil Jimenez, K Silina, K Hendricksen, L Smit, J De Feijter, ...
Journal of Clinical Oncology 38 (15_suppl), 5020-5020, 2020
62020
Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer
M Rijnders, JA Nakauma-González, DGJ Robbrecht, A Gil-Jimenez, ...
Nature Communications 15 (1), 1349, 2024
12024
The penile cancer tumor microenvironment and immunotherapy response: Results from the PERICLES trial
TS Rafael, A Gil-Jimenez, HM de Vries, IM Seignette, E Bekers, ...
Cancer Research 84 (6_Supplement), 2488-2488, 2024
2024
Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors
A Gil-Jimenez, N van Dijk, JL Vos, Y Lubeck, ML van Montfoort, D Peters, ...
Nature Communications 15 (1), 2538, 2024
2024
Corrigendum to" Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer"[Eur Urol 2023; 83: 313-17]
A Gil-Jimenez, J van Dorp, A Contreras-Sanz, K van der Vos, DJ Vis, ...
European urology 83 (6), e165, 2023
2023
Spatial relationships in the tumor microenvironment predict response to immune checkpoint inhibitors in urothelial and head and neck cancer
A Gil-Jimenez, N van Dijk, Y Lubeck, ML van Montfoort, D Peters, ...
Cancer Research 83 (7_Supplement), 5786-5786, 2023
2023
Predicting pathological response after ipilimumab plus nivolumab in stage III urothelial cancer by liquid biopsy assessment of plasma and urine ctDNA using the RaDaR assay
J van Dorp, C Pipinikas, N van Dijk, G Jones, A Gil-Jimenez, G Marsico, ...
Cancer Research 82 (12), 2022
2022
T Cell-to-Stroma Enrichment (TSE) score: a gene expression metric that predicts response to immune checkpoint inhibitors in patients with urothelial cancer
M Rijnders, JA Nakauma-González, DGJ Robbrecht, A Gil-Jimenez, ...
bioRxiv, 2022.05. 30.493997, 2022
2022
The system can't perform the operation now. Try again later.
Articles 1–12